UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman
Provided By PR Newswire
Last update: May 29, 2025
URGN Investors with Losses Encouraged to Contact Hagens Berman
SAN FRANCISCO, May 29, 2025 /PRNewswire/ -- On May 21, 2025, investors in UroGen Pharma Ltd. (NASDAQ: URGN) saw the price of their shares crash 44% after the company announced that the FDA's Oncologic Drugs Advisory Committee ("ODAC") voted against the risk/benefit profile of UroGen's UGN-102, a therapy intended to treat patients with low-grade, intermediate-risk non-muscle invasive bladder cancer ("LG-IR-NMIBC") for which no drugs are currently FDA-approved.
Read more at prnewswire.com5
+0.16 (+3.31%)
Find more stocks in the Stock Screener
URGN Latest News and Analysis
18 days ago - ChartmillLet's have a look at the top gainers and losers one hour before the close of the markets of today's session.Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
18 days ago - ChartmillTop stock movements in today's session.Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
19 days ago - ChartmillThe market is filled with gapping stocks in Friday's session.The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.
